SURF - Surface Oncology's SRF617 gets FDA orphan drug status

Surface Oncology (SURF) announces that the U.S. FDA has granted Orphan Drug Designation for one of the company’s lead therapeutic candidates, SRF617, for the treatment of patients with pancreatic cancer.Programs with Orphan Drug status receive partial tax credit for clinical trial expenditures, waived user fees and eligibility for seven years of marketing exclusivity.In preclinical studies, SRF617 has exhibited strong affinity for and inhibition of CD39, the ability to reduce adenosine and increase ATP levels and anti-tumor activity both as a single agent and in combination with multiple therapeutic agents, the company said.Shares up nearly 6% after market.

For further details see:

Surface Oncology’s SRF617 gets FDA orphan drug status